233 related articles for article (PubMed ID: 37782910)
21. Off-the-Shelf Chimeric Antigen Receptor Immune Cells from Human Pluripotent Stem Cells.
Cao H; Sugimura R
Cancer Treat Res; 2022; 183():255-274. PubMed ID: 35551663
[TBL] [Abstract][Full Text] [Related]
22. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions.
Zhang L; Tian L; Dai X; Yu H; Wang J; Lei A; Zhu M; Xu J; Zhao W; Zhu Y; Sun Z; Zhang H; Hu Y; Wang Y; Xu Y; Church GM; Huang H; Weng Q; Zhang J
J Hematol Oncol; 2020 Nov; 13(1):153. PubMed ID: 33176869
[TBL] [Abstract][Full Text] [Related]
23. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
Nguyen S; Lacan C; Roos-Weil D
Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
[TBL] [Abstract][Full Text] [Related]
24. Prospects for Development of Induced Pluripotent Stem Cell-Derived CAR-Targeted Immunotherapies.
Mazza R; Maher J
Arch Immunol Ther Exp (Warsz); 2021 Dec; 70(1):2. PubMed ID: 34897554
[TBL] [Abstract][Full Text] [Related]
25. Targeted integration of EpCAM-specific CAR in human induced pluripotent stem cells and their differentiation into NK cells.
Tang SY; Zha S; Du Z; Zeng J; Zhu D; Luo Y; Wang S
Stem Cell Res Ther; 2021 Nov; 12(1):580. PubMed ID: 34802459
[TBL] [Abstract][Full Text] [Related]
26. Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma.
Harada S; Ando M; Ando J; Ishii M; Yamaguchi T; Yamazaki S; Toyota T; Ohara K; Ohtaka M; Nakanishi M; Shin C; Ota Y; Nakashima K; Ohshima K; Imai C; Nakazawa Y; Nakauchi H; Komatsu N
Mol Ther; 2022 Feb; 30(2):534-549. PubMed ID: 34628050
[TBL] [Abstract][Full Text] [Related]
27. CAR-NK cells from engineered pluripotent stem cells: Off-the-shelf therapeutics for all patients.
Lu SJ; Feng Q
Stem Cells Transl Med; 2021 Nov; 10 Suppl 2(Suppl 2):S10-S17. PubMed ID: 34724715
[TBL] [Abstract][Full Text] [Related]
28. Current approaches to develop "off-the-shelf" chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review.
Aparicio C; Acebal C; González-Vallinas M
Exp Hematol Oncol; 2023 Aug; 12(1):73. PubMed ID: 37605218
[TBL] [Abstract][Full Text] [Related]
29. The Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular Immunotherapeutics.
Mehra V; Chhetri JB; Ali S; Roddie C
Biology (Basel); 2023 Nov; 12(11):. PubMed ID: 37998018
[TBL] [Abstract][Full Text] [Related]
30. [Development of CAR-T cell therapy using allogeneic iPS cells].
Kaneko S
Rinsho Ketsueki; 2022; 63(10):1454-1460. PubMed ID: 36351655
[TBL] [Abstract][Full Text] [Related]
31. Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials.
Smirnov S; Petukhov A; Levchuk K; Kulemzin S; Staliarova A; Lepik K; Shuvalov O; Zaritskey A; Daks A; Fedorova O
Front Immunol; 2021; 12():780145. PubMed ID: 34975869
[TBL] [Abstract][Full Text] [Related]
32. A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy.
Iriguchi S; Yasui Y; Kawai Y; Arima S; Kunitomo M; Sato T; Ueda T; Minagawa A; Mishima Y; Yanagawa N; Baba Y; Miyake Y; Nakayama K; Takiguchi M; Shinohara T; Nakatsura T; Yasukawa M; Kassai Y; Hayashi A; Kaneko S
Nat Commun; 2021 Jan; 12(1):430. PubMed ID: 33462228
[TBL] [Abstract][Full Text] [Related]
33. New cell sources for T cell engineering and adoptive immunotherapy.
Themeli M; Rivière I; Sadelain M
Cell Stem Cell; 2015 Apr; 16(4):357-66. PubMed ID: 25842976
[TBL] [Abstract][Full Text] [Related]
34. CAR-Modified Vγ9Vδ2 T Cells Propagated Using a Novel Bisphosphonate Prodrug for Allogeneic Adoptive Immunotherapy.
Wang Y; Wang L; Seo N; Okumura S; Hayashi T; Akahori Y; Fujiwara H; Amaishi Y; Okamoto S; Mineno J; Tanaka Y; Kato T; Shiku H
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446055
[TBL] [Abstract][Full Text] [Related]
35. Induced CAR-Macrophages as a Novel Therapeutic Cell Type for Cancer Immune Cell Therapies.
Su S; Lei A; Wang X; Lu H; Wang S; Yang Y; Li N; Zhang Y; Zhang J
Cells; 2022 May; 11(10):. PubMed ID: 35626689
[TBL] [Abstract][Full Text] [Related]
36. Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.
Muller YD; Ferreira LMR; Ronin E; Ho P; Nguyen V; Faleo G; Zhou Y; Lee K; Leung KK; Skartsis N; Kaul AM; Mulder A; Claas FHJ; Wells JA; Bluestone JA; Tang Q
Front Immunol; 2021; 12():686439. PubMed ID: 34616392
[TBL] [Abstract][Full Text] [Related]
37. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
38. Apoptosis inhibition enhances induced pluripotent stem cell generation during T cell reprogramming.
Ren J; Zhang X; Zhang Z; Pan J; Hao Z; Li J; Liu J
Biochem Biophys Res Commun; 2023 May; 656():30-37. PubMed ID: 36947964
[TBL] [Abstract][Full Text] [Related]
39. Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia.
Abdin SM; Paasch D; Kloos A; Oliveira MC; Jang MS; Ackermann M; Stamopoulou A; Mroch PJ; Falk CS; von Kaisenberg CS; Schambach A; Heuser M; Moritz T; Hansen G; Morgan M; Lachmann N
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38135346
[TBL] [Abstract][Full Text] [Related]
40. TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens.
Akatsuka Y
Front Immunol; 2020; 11():257. PubMed ID: 32184779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]